Figure 2

RA treatment of bone marrow myeloid cells produces mature myeloid cells. Bone marrow cells were differentiated in the presence of GM-CSF with or without 100 nM of either estriol or retinoic acid over 6–7 days of differentiation. Cells were routinely stained for flow cytometry using antibodies against CD11c-, CD11b⁺, CD80, CD86, MHC class II, PD-L1 and PD-L2, run of a BD Accuri C6 flow cytometer and phenotypic profiles evaluated using the Cflow plus software program. Cells were evaluated for the presence of maturation (activation) markers (A) CD80, CD86 MHCII, and the inhibitory co-stimulatory markers (B) PD-L1and PD-L2. (C) Mean fluorescence intensity (MFI) was determined and relative expression shown by overlays of cell treatment groups and MFI values (D). Data are representative of at least three separate experiments.